Advantages to Treating HR+ Patients With Breast Cancer With Abemaciclib

Nicole Lamanna, MD, discussed some of the ongoing clinical trials evaluating new therapies for patients with chronic lymphocytic leukemia.

At the 42nd Annual Chemotherapy Foundation Symposium, Erin Mulvey, MD, discussed the significant progress being made in the treatment of relapsed or refractory follicular lymphoma.

In an interview with Targeted Oncology, Courtney Van Houzen, PharmD, shared her experience in bringing bispecific antibody treatments to a community setting.

Meredith McKean, MD, MPH, discussed findings from a longer-term follow-up study evaluating fianlimab plus cemiplimab for the treatment of metastatic melanoma.

A new study suggests that patients with multiple myeloma who achieve sustained MRD-negativity for at least three years may be able to discontinue maintenance therapy without compromising their long-term outcomes.